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Abstract
Background: Pregnant women develop protective anti-VSA IgG1 and IgG3 when infected by
Plasmodium falciparum. The major target of IgG from serum of infected pregnant women is
VAR2CSA.
Methods: In this study, ELISA was used to compare the level of VAR2CSA DBL5ε- specific IgG
subclasses at enrolment and at delivery in a cohort of pregnant women in Senegal. All antibody
measures were analysed in relation to placental infection according to parity.
Results: The results show an interaction between immune response to placental malaria and
parity. A higher level of anti- DBL5ε- IgG3 at enrolment and a higher increase between enrolment
and delivery were found in primigravidae who presented with uninfected placenta at delivery in
comparison to those who presented with an infection of the placenta. However, high antibody level
at delivery was associated with the infection of the placenta in multigravidae.
Conclusion: This high level of IgG3 in uninfected primigravidae suggests a protective role of these
antibodies in this susceptible group, highlighting the importance of VAR2CSA in general and of
some of its variants still to be defined, in the induction of protective immunity to pregnancy malaria.
Background
Plasmodium falciparum-infected erythrocytes (IE) are able
to bind various host receptors via the expression of variant
surface antigens (VSAs) on the erythrocyte surface. Plasmo-
dium falciparum erythrocyte membrane protein 1
(PfEMP1) is a VSA located on the IE surface, which under-
goes clonal antigenic variation. Acquired protection
against malaria is mediated, at least partially, by IgG tar-
geting PfEMP1 [1]. Although this antibody response may
directly inhibit IE adhesion to endothelial cells, it also
might be implicated in opsonization. IgG1 and IgG3 are
responsible for pathogen clearance via opsonization, sen-
sitization of NK cells, and/or activation of the comple-
ment system [2]. A few studies have examined the pattern
of IgG subtypes in the antimalarial response and have
underlined the role of the anti-VSA cytophilic IgG (IgG1
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and IgG3) in protection from malaria [3-5]. In vitro, these
IgG mediate the phagocytosis of IE [6], a mechanism that
may also play a major role in parasite elimination in
humans.
Pregnancy-associated malaria (PAM) results in infant low
birth weight, and maternal anaemia. IE accumulate in the
placental intervillous space and bind to chondroitin sul-
fate A (CSA) via a specific PfEMP1 variant, VAR2CSA [7].
This protein is comprised of six Duffy binding like (DBL)
domains, several of which (including DBL2X, DBL3X,
DBL5ε-, DBL6ε-) have been shown to bind to CSA [8,9].
After successive pregnancies, women develop protective
IgG antibodies against placental parasites. Serum from
pregnant women from different geographical areas are
able to recognize the surface of IE from pregnant women,
suggesting that the antigenic target must be relatively con-
served. Anti-VAR2CSA antibody levels correlate with the
decrease of the rates of placental infection, low birth
weight and maternal anaemia, and with the ability of the
serum to inhibit the adhesion of IE to CSA (reviewed in
[1]).
Two studies [10,11] demonstrate that anti-VSA IgG1 and
IgG3 are the main antibody subclasses implicated in the
anti-PAM response. Levels of IgG1 and IgG3 correlate with
serum ability to inhibit the adhesion of IE to CSA in vitro.
Larger studies are needed to determine if IgG1 and IgG3
are protective in pregnant women and to determine their
target. As var2csa is over-expressed in placental parasites,
and as anti-VAR2CSA IgG inhibit the IE adhesion to CSA
and are associated with protection from PAM [12,13],
whether or not malaria infection during pregnancy is able
to induce VAR2CSA specific IgG1 and IgG3 was further
examined. The level of DBL5ε- specific antibodies at
enrolment and at delivery was compared in a cohort of
pregnant women in relation to placental infection accord-
ing to parity.
Methods
Pregnant women were enrolled in a cohort study between
30 July and 15 October 2001 in Thiadiaye, 130 km east
from Dakar [13]. Briefly, women pregnant for less than 6
months were enrolled if they were not infected with
malaria parasites at that time, declared not to have had
malaria since being pregnant, and were likely to be
exposed to infective mosquito bites during their preg-
nancy. A total of 306 pregnant women were followed by
active and passive detection through monthly ANC visits
and through weekly home visits until delivery. Women
presenting with fever and a positive blood smear were
given curative treatment with chloroquine, the first-line
antimalarial drug in Senegal at that time. However, 55/
111 malarial infections were symptomless and detected
afterwards by active case survey. At delivery, peripheral
and placental blood was investigated by microscopy for
the presence of malaria parasites.
The DBL5ε- domain of VAR2CSA from 3D7 was produced
in baculovirus-infected SF9 cells, as described [12-14].
Recombinant MSP1 (yPfMSP1–19) was used as a control.
Optimal concentrations of each protein were coated in
96-well plates, and the different subtypes of specific IgG
were measured by ELISA. Plates were coated with 1 μg/mL
concentrations of antigen. Wells were incubated with 100
μL of human plasma at dilutions optimized for each
measure (1:200 for total IgG, 1:100 for IgG1 and IgG3,
1:50 for IgG2 and IgG4), followed by horseradish peroxi-
dase-conjugated anti-human IgG (1:15,000) for total IgG
measures. For the remaining IgG subclasses, purified
mouse monoclonal antibodies against human IgG1
(clone MH1013, Caltag laboratories, Burlingame, CA),
IgG2 (clone: MH1022, Caltag laboratories, Burlingame,
CA), IgG3 (clone: MH1032, Caltag laboratories, Burlin-
game, CA) or IgG4 (clone: MH1042, Caltag laboratories,
Burlingame, CA) were used. All reagents were used at pre-
determined optimal dilutions.
The optical density (OD) was obtained by subtracting the
average OD of duplicate wells from that of the corre-
sponding blank wells. Values were converted into arbi-
trary units (AUs), as follows:
Serum from 13 young Senegalese children, 18 French
adult men and 31 French pregnant women were included
as controls. Antibody responders were defined as those
having an antibody level (in AU) > 2SDs above the mean
absorbance of the negative control.
Analyses were performed with each antibody sub-class
(IgG1, IgG2, IgG3, IgG4) in women with one detected
malarial infection or more during the follow-up. For each
sub-class, three "antibody variables" were created: the
level of antibody at enrolment, the level of antibody at
delivery, and the variation between enrolment and deliv-
ery (level at delivery – level at enrolment). These three
"antibody variables" were compared by Wilcoxon test
between women presenting with a placental infection at
delivery (positive placental blood smear) vs. those with-
out placental infection. Analyses were stratified on parity
(primigravidae and multigravidae).
As the onset of a febrile episode during the follow-up (and
the subsequent treatment) is a potential confounder in
this analysis, a "febrile episode" dummy variable has been
created: existence or not of one or more febrile episodes
during the follow-up. The relation between this variable
AU OD test sample OD negative control
OD positiv =× − 100 [ ln ( ) ln ( )
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and each of the three "antibody variables" was checked by
Wilcoxon test (stratified on parity). When both "febrile
episode" and "placental infection" variables showed sig-
nificant difference of antibodies levels, they were simulta-
neously entered in a multivariate linear regression model.
Results
Study population
Among the 306 women, 12 were lost to follow-up, and at
least one serum sample was lacking for 56 of them: anti-
body titres were measured in 261 women at enrolment,
and in 240 at delivery. Among the 238 women having
antibody measurements at both enrolment and delivery,
53 were primigravidae (22.3%) and 185 multigravidae
(77.7%). The prevalence of placental infection (positive
blood smear) was around 15% (35/238) at delivery. A
total of 138 women did not present with a P. falciparum
infection during the follow-up and had measures of anti-
body titres at enrolment and at delivery; the mean levels
of IgG3 antibodies was unchanged, at 32.4 (sd = 37.7)
and 34.7 (sd = 38.1) AU respectively. One hundred and
eleven women presented with at least one P. falciparum
infection during the follow-up, and measures of antibody
titres at enrolment, 100 of these also had antibody meas-
urement at delivery. Among these 111 women, 56 pre-
sented at least once during the follow-up with a malaria
clinical attack requiring treatment. The other 55 presented
with asymptomatic infections, and therefore did not
receive antimalarial treatment.
Seroreactivity of anti- DBL5ε- IgG
It has been shown that plasma level of VSA-specific IgG is
dominated by IgG1. High levels of anti- DBL5ε- IgG1 and
IgG3 were observed in the present cohort of senegalese
pregnant women both at enrolment and at delivery.
In a global analysis for all the women, all subclasses levels
increased between enrolment and delivery (all p < 0.001)
(Figure 1). The plasma levels of IgG anti-MSP1 did not
vary significatively between enrolment and delivery (p =
0.13), as previously described for IgG directed against non
PAM-VSAs [11]. Total IgG anti-DBL5ε- did not vary
between enrolment and delivery in primigravidae and in
multigravidae (p = 0.24 and 0.95 respectively), whereas
all IgG subclasses levels significantly increased between
enrolment and delivery in primigravidae as well as in mul-
tigravidae (all p < 0.02) excepted the IgG4 level that did
not increase in primigravidae (p = 0.13).
The only subclass, that showed significant differences
between women with infected and uninfected placenta at
delivery, according to parity, was IgG3 and only the results
concerning this subclass will, therefore, be detailed here.
Serum IgG3 level to VAR2CSA DBL5ε-
Anti-DBL5ε- IgG3 levels in the 111 women infected dur-
ing pregnancy and who presented with or without placen-
tal infection are shown in Table 1. The results show two
opposite situations according to parity. In primigravidae,
women without placental infection presented with higher
IgG3 levels for the three "antibody variables" at enrol-
ment, at delivery, and variation between enrolment and
delivery (the difference at enrolment was only marginally
significant, p < 0.1, probably due to a lack of power result-
ing from the small sample size), as compared to women
with placental infection. This relation was not modified
when the "febrile episode variable" was taken into
account. On the contrary, in multigravidae higher levels of
IgG3 were observed in women with infected placenta
(only significant at delivery). The variation between enrol-
ment and delivery was significant in the univariate analy-
sis (p = 0.04), but not when the "febrile episode variable"
was taken into account (p = 0.21). Neither other anti-
DBL5ε- subclasses, nor anti-MSP1 IgG3 antibodies were
related to placental infection when similar analyses were
performed (all p > 0.10).
Discussion
The aim of this study was to compare the acquisition of
the different sub-classes of VAR2CSA-specific antibodies
in primigravidae and multigravidae and to assess their
role in protection from placental infection. Previously
[13], the level of total IgG against recombinant DBL1X,
DBL5ε- and DBL6ε- in the same cohort of women as
determined at enrolment and at delivery showed that sig-
nificant increases were associated with women who expe-
rienced at least one peripheral parasitemia during the
survey. In the current study, the total IgG level was similar
at both dates in women who never presented with a posi-
tive thick blood smear during their pregnancy. Further-
more, some (5/138) of these women presented with a
placental infection, revealing an infection not detected
during the follow-up. Thus, further analysis focussed
towards women with one or more proven malarial infec-
tion during pregnancy.
IgG directed against the DBL5ε- domain seem to be repre-
sentative of the immune response to placental parasites:
anti-DBL5ε- IgG level correlates with anti-VSAs IgG level
and with parity, women with a high level of anti-DBL5ε-
IgG at enrolment were shown to more likely present with
an uninfected placenta at delivery [13]. Furthermore,
monoclonal antibodies inhibiting IE adhesion to placen-
tal cryosection are able to recognize recombinant DBL5ε-
[8]. Therefore, a refined analysis of the anti-DBL5ε-
response in these women was justified.Malaria Journal 2008, 7:10 http://www.malariajournal.com/content/7/1/10
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Parity-dependency of the plasma antibody reactivity to VAR2CSA and MSP119 recombinant proteins Figure 1
Parity-dependency of the plasma antibody reactivity to VAR2CSA and MSP119 recombinant proteins. ELISA was 
carried out on DBL5ε- and MSP119 coated plates. IgG, IgG1, IgG2, IgG3, and IgG4 directed against DBL5ε-, as well as against 
MSP119 . Antibody plasma levels are expressed as arbitrary units (AU) and are shown at enrolment and at delivery for primi-
gravid (panel A, n = 53) and multigravid women (panel B, n = 185) from Senegal. The top, bottom, and line through the middle 
of the box correspond to the 75th percentile, 25th percentile, and 50th percentile (median), respectively. The whiskers on the 
bottom extend from the 10th percentile and top 90th percentile.
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IgG3 was the only isotype of anti-DBL5ε- IgG showing a
significant difference between women with a placenta
infected or not, according to parity, thus only the results
concerning this subclass is presented here. In primigravi-
dae infected during pregnancy, the level of IgG3 was
higher at delivery than at enrolment. This suggests that
this IgG subtype is predominantly implicated in the
acquisition of immunity against a placental infection, as
reported by Megnekou et al. [11] and Elliott et al. [10] for
antibodies to VSAs, and that IgG3 predominantly recog-
nize DBL5ε- among the repertoire of VSAs.
Anti- DBL5ε- IgG3 levels at enrolment increased with par-
ity (p = 0.08), in line with other studies showing that
primigravidae have lower levels of IgG against IE surface
antigens than multigravidae [15]. This high level of IgG3
in multigravidae may be, at least partially, responsible for
the reduced susceptibility to PAM. Primigravidae present-
ing with a placental infection at delivery, had a lower level
of anti-DBL5ε- IgG3 at enrolment, at delivery, and a
smaller variation of these antibodies between enrolment
and delivery, than primigravidae without placental infec-
tion, suggesting that these antibodies could have an
impact in preventing placental infections. The levels of
IgG3 in 21 Cameroonese primigravidae (enrolled in 1993
in Ebolowa, 160 km south from Yaounde) was analysed
according to placental infection (data not shown). The
same trend but not significant (probably due to the small
sample size) was observed. In term of public health, this
protective effect seems important since primigravidae are
the most susceptible to PAM consequences. In contrast, in
multigravidae, placental infection was not related with the
level of anti-DBL5ε- IgG3 at enrolment, but was associ-
ated to a higher level of anti-DBL5ε- IgG3 at delivery. In
this situation, these antibodies seem to react as a marker
of infection rather than as a marker of protection from
PAM.
A similar interaction between placental malaria and gra-
vidity was reported for the risk of parasitemia in infancy.
Infants born from infected primigravidae have a lower risk
of parasitemia than infants born from uninfected primi-
gravidae. Whereas, the risk is reversed in multigravidae,
with infants born from infected multigravidae having a
higher risk of parasitaemia [16].
Selected DBL3X sequence motifs in VAR2CSA are more
likely encountered in parasites from primigravidae, while
other motifs are more likely present in multigravidae [9].
A similar mechanism may occur for other VAR2CSA
domains, and even other VSAs, with parasites infecting
primigravidae and multigravidae expressing different var-
iants. Human are often infected by multiple variants that
will compete for host resources, often resulting in one var-
iant emerging among the population [17]. It could be
hypothesized that parasites infecting pregnant women
commonly express a particular DBL5ε-, conferring a high
binding capacity, representing a biological advantage in
pregnant women. First-time pregnant women are likely to
be infected by this variant, that will be able to outgrow
and fastly dominate rarer and less advantaged variants.
Those variants that are frequent in the most susceptible
group of primigravid women are probably the most viru-
lent and would be of particular interest in the develop-
ment of efficient vaccine against PAM. High level of
protective IgG aquired against common variants during
first pregnancies will favour establishment of new and less
frequent variants in multigravidae. Thus, the inverted rela-
tion observed in this study supports distincts mechanisms
according to parity and also probaly to variants. While the
protectiveness of anti-DBL5ε- IgG3 subclass in primigravi-
dae is clear, this can rather turn to a marker for infection
in multigravidae.
Table 1: Levels of IgG3 according to placental infection and parity
Uninfected placenta Infected placenta P value **
No Mean (sd*) No Mean (sd)
Primigravidae 14 27.0 (33.9) 13 14.5 (29.0) 0.09
Enrolment Multigravidae 67 36.8 (42.7) 17 42.7 (53.9) 0.54
Primigravidae 13 64.3 (21.6) 12 39.2 (24.7) 0.03
Delivery Multigravidae 59 45.7 (37.4) 16 73.4 (30.6) 0.01
Variation Primigravidae 13 41.9 (24.9) 12 23.5 (29.3) 0.06
delivery – enrolment Multigravidae 59 10.6 (40.2) 16 28.0 (63.8) 0.21
* sd, standard deviation
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Conclusion
Results presented here highlight the fact that VAR2CSA
possesses immunogenic epitopes that can be of major
interest for any vaccination strategy aiming to provide
protection to primigravidae which are most at risk. It
seems, therefore, important to pursue the sequence analy-
ses of the various DBLs of the VAR2CSA expressed by pla-
cental parasites isolated from different parities, in order to
determine critical epitopes.
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